Technical Analysis for PVCTW - Provectus Biopharmaceuticals Inc. Warrant

Grade Last Price % Change Price Change
grade F 0.0056 -53.33% -0.0064
PVCTW closed down 53.33 percent on Friday, October 18, 2019, on 1.39 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical PVCTW trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
50 DMA Support Bullish -53.33%
Wide Bands Range Expansion -53.33%
Crossed Above 20 DMA Bullish -57.89%
Crossed Above 50 DMA Bullish -57.89%
Wide Bands Range Expansion -57.89%
Gapped Up Strength -57.89%

Older signals for PVCTW ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus’ investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com or contact Porter, LeVay & Rose, Inc.
Medicine RTT Medical Specialties Organ Systems Immunotherapy Autoimmune Diseases Breast Cancer Fda Psoriasis Atopic Dermatitis Melanoma Biopharmaceuticals Hepatocellular Carcinoma Dermatitis Liver Cancer Metastatic Melanoma Solid Tumor Cancers National Institute Of Health Skin Cancer
Is PVCTW a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 0.089
52 Week Low 0.0005
Average Volume 47,703
200-Day Moving Average 0.0146
50-Day Moving Average 0.01
20-Day Moving Average 0.0078
10-Day Moving Average 0.0072
Average True Range 0.0038
ADX 15.8
+DI 29.4695
-DI 38.3104
Chandelier Exit (Long, 3 ATRs ) 0.0046
Chandelier Exit (Short, 3 ATRs ) 0.0145
Upper Bollinger Band 0.0143
Lower Bollinger Band 0.0013
Percent B (%b) 0.33
BandWidth 166.666667
MACD Line -0.0006
MACD Signal Line -0.001
MACD Histogram 0.0004
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0118
Resistance 3 (R3) 0.0117 0.0096 0.0107
Resistance 2 (R2) 0.0096 0.0080 0.0096 0.0104
Resistance 1 (R1) 0.0076 0.0071 0.0066 0.0077 0.0100
Pivot Point 0.0055 0.0055 0.0050 0.0055 0.0055
Support 1 (S1) 0.0035 0.0039 0.0025 0.0036 0.0012
Support 2 (S2) 0.0014 0.0030 0.0014 0.0008
Support 3 (S3) -0.0006 0.0014 0.0005
Support 4 (S4) -0.0006